<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02498860</url>
  </required_header>
  <id_info>
    <org_study_id>CNUHH-2015-7</org_study_id>
    <nct_id>NCT02498860</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Adjuvant Pemetrexed Plus Cisplatin for Adenocarcinoma of Lung</brief_title>
  <acronym>APICAL</acronym>
  <official_title>Efficacy and Safety of Pemetrexed Plus Cisplatin as Combination Chemotherapy for Post-operative Adenocarcinoma : Multi-center, Single Arm, Open-label, Phase Ⅱ Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chonnam National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Kosin University Gospel Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Korea University Guro Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Severance Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chungnam National University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Kyungpook National University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Pusan National University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Chonnam National University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Two-Year Disease Free Survival Rate of Stage IB~IIIA adenocarcinoma after Adjuvant&#xD;
      Chemotherapy with Pemetrexed and Cisplatin will be assessed. A total of 106 patients will be&#xD;
      recruited for 12 months, and followed for two years, thus the duration of study will be 36&#xD;
      months.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary endpoint : 2 year disease free survival&#xD;
&#xD;
      Secondary endpoints:&#xD;
&#xD;
      Overall survival, Frequency and severity of adverse events&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 1, 2015</start_date>
  <completion_date type="Actual">July 31, 2021</completion_date>
  <primary_completion_date type="Actual">February 6, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease free survival rate</measure>
    <time_frame>2 year</time_frame>
    <description>Disease free survival time is measured from the date of enrollment to date of tumor recurrence.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>4 year</time_frame>
    <description>Overall survival time is measured from the date of enrollment to date of death from any cause. Participants who are alive when the data lock or is lost to follow-up will have their overall survival time censored on the last date the participant is known to be alive.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>4 months</time_frame>
    <description>adverse events using common terminology criteria for adverse events 4.0</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">106</enrollment>
  <condition>Adenocarcinoma</condition>
  <condition>Lung Neoplasm</condition>
  <arm_group>
    <arm_group_label>Pemebit plus Cisplatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pemetrexed (Pemebit 500 mg/m2) plus cisplatin (75 mg/m2) every 3 weeks up to 4 cycles</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pemebit</intervention_name>
    <description>500mg/m2 on day 1 of every 3-week cycle, for a maximum of 4 cycles</description>
    <arm_group_label>Pemebit plus Cisplatin</arm_group_label>
    <other_name>Pemetrexed</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>75mg/m2 on day 1 of every 3-week cycle, for a maximum of 4 cycles</description>
    <arm_group_label>Pemebit plus Cisplatin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adenocarcinoma of Lung&#xD;
&#xD;
          -  Postoperative pathologic stage IB~IIIA&#xD;
&#xD;
          -  Complete surgical resection (R0 resection) N1-2: R0 resection with lobectomy and&#xD;
             mediastinal lymph nodes dissection (MLND) N0: R0 resection with lobectomy with or&#xD;
             without MLND&#xD;
&#xD;
          -  Adjuvant treatment should start between 4 to 6 weeks after surgery&#xD;
&#xD;
          -  ECOG performance status 0-1&#xD;
&#xD;
          -  Weight loss during last 3 months should be less than 10%.&#xD;
&#xD;
          -  Normal hematologic, hepatic and renal function Neutrophil count &gt; 1500 /microliter,&#xD;
             Platelet &gt; 100,000/microliter, Hemoglobin &gt; 9 g/dL Bilirubin &lt;=1.5 x upper limit&#xD;
             normal, transaminase &lt; 2.5 x upper limit normal Serum Creatinine &lt;=1.5 mg/dL&#xD;
&#xD;
          -  Women in child bearing age should consent using contraceptive measures, and must have&#xD;
             negative pregnancy test.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Other malignant neoplastic disease within 5 years.&#xD;
&#xD;
          -  Neoadjuvant chemotherapy before surgery of lung cancer&#xD;
&#xD;
          -  Patients who will be treated with postoperative radiation.&#xD;
&#xD;
          -  Stage IIIB or IV lung cancer&#xD;
&#xD;
          -  Severe infection, or cardiorespiratory, hematologic illness&#xD;
&#xD;
          -  HIV positive cases&#xD;
&#xD;
          -  Pregnancy or lactating women&#xD;
&#xD;
          -  Autoimmune diseases or those who receiving immune suppressive treatment&#xD;
&#xD;
          -  Symptomatic neuropathy &gt; CTCAE grade 1&#xD;
&#xD;
          -  Those who consented other clinical trials within 3 months&#xD;
&#xD;
          -  Other significant medical conditions contraindicated to clinical trial&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Young-Chul Kim, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Chonnam National University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Chonnam National University Hwasun Hospital</name>
      <address>
        <city>Hwasun</city>
        <state>Jeonnam</state>
        <zip>519-763</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kyungpook National University Medical Center</name>
      <address>
        <city>Daegu</city>
        <state>Kyungpook</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chungnam National University Hospital</name>
      <address>
        <city>Daejeon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pusan National University Hospital</name>
      <address>
        <city>Pusan</city>
        <zip>602-739</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kosin University Gospel Hospital</name>
      <address>
        <city>Pusan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Korea university Guro hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Severance hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <results_reference>
    <citation>Kreuter M, Vansteenkiste J, Fischer JR, Eberhardt W, Zabeck H, Kollmeier J, Serke M, Frickhofen N, Reck M, Engel-Riedel W, Neumann S, Thomeer M, Schumann C, De Leyn P, Graeter T, Stamatis G, Zuna I, Griesinger F, Thomas M; TREAT investigators. Randomized phase 2 trial on refinement of early-stage NSCLC adjuvant chemotherapy with cisplatin and pemetrexed versus cisplatin and vinorelbine: the TREAT study. Ann Oncol. 2013 Apr;24(4):986-92. doi: 10.1093/annonc/mds578. Epub 2012 Nov 15.</citation>
    <PMID>23161898</PMID>
  </results_reference>
  <results_reference>
    <citation>Douillard JY, Rosell R, De Lena M, Carpagnano F, Ramlau R, Gonzáles-Larriba JL, Grodzki T, Pereira JR, Le Groumellec A, Lorusso V, Clary C, Torres AJ, Dahabreh J, Souquet PJ, Astudillo J, Fournel P, Artal-Cortes A, Jassem J, Koubkova L, His P, Riggi M, Hurteloup P. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial. Lancet Oncol. 2006 Sep;7(9):719-27. Erratum in: Lancet Oncol. 2006 Oct;7(10):797.</citation>
    <PMID>16945766</PMID>
  </results_reference>
  <results_reference>
    <citation>Olaussen KA, Dunant A, Fouret P, Brambilla E, André F, Haddad V, Taranchon E, Filipits M, Pirker R, Popper HH, Stahel R, Sabatier L, Pignon JP, Tursz T, Le Chevalier T, Soria JC; IALT Bio Investigators. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med. 2006 Sep 7;355(10):983-91.</citation>
    <PMID>16957145</PMID>
  </results_reference>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>July 13, 2015</study_first_submitted>
  <study_first_submitted_qc>July 14, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 15, 2015</study_first_posted>
  <last_update_submitted>August 1, 2021</last_update_submitted>
  <last_update_submitted_qc>August 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chonnam National University Hospital</investigator_affiliation>
    <investigator_full_name>Young-Chul Kim</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>adenocarcinoma</keyword>
  <keyword>lung</keyword>
  <keyword>adjuvant chemotherapy</keyword>
  <keyword>pemetrexed</keyword>
  <keyword>cisplatin</keyword>
  <keyword>surgery</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pemetrexed</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

